ReviewDrug safety2009
Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.
Review in Drug safety, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.BMJ (Clinical research ed.) · 2012Trial
- Effect of sildenafil citrate on intraocular pressure and blood pressure in human volunteers.Experimental eye research · 2011Trial
- Comparative tolerability of targeted therapies in pulmonary hypertension.Archives of medical science : AMS · 2024Review
- Rare vardenafil-associated Stevens-Johnson syndrome: toxic epidermal necrolysis.BMJ case reports · 2022Article
- Photoreceptor Phosphodiesterase (PDE6): Structure, Regulatory Mechanisms, and Implications for Treatment of Retinal Diseases.Advances in experimental medicine and biology · 2022Review
- Photoreceptor phosphodiesterase (PDE6): activation and inactivation mechanisms during visual transduction in rods and cones.Pflugers Archiv : European journal of physiology · 2021Review
- Intoxication with Ornithogalum arabicum is a potential cause of visual impairment and irreversible blindness in dogs.Toxicon: X · 2019Article
- Simultaneous analysis of 23 illegal adulterated aphrodisiac chemical ingredients in health foods and Chinese traditional patent medicines by ultrahigh performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry.Journal of food and drug analysis · 2018Article
- Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2018Article
- Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
- Sildenafil and retinopathy of prematurity risk in very low birth weight infants.Journal of perinatology : official journal of the California Perinatal Association · 2016Article
- Translational Preclinical Research may Lead to Improved Medical Management of Non-Arteritic Anterior Ischemic Optic Neuropathy.Frontiers in neurology · 2014Review
- Optic neuropathy associated with the use of over-the-counter sexual enhancement supplements.Clinical ophthalmology (Auckland, N.Z.) · 2014Article
- Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.Therapeutics and clinical risk management · 2014Review
- Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.The Journal of biological chemistry · 2012Article
- [Pharmacological concepts to treat hereditary retinal degenerations].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2012Review
- Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.Drug design, development and therapy · 2010Review
- Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions.The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique · 2010Article
- Safety and quality assessment of 175 illegal sexual enhancement products seized in red-light districts in Singapore.Drug safety · 2009Article
- Anterior Ischemic Optic Neuropathy in a Patient with Erectile Dysfunction: Tadalafil as an Offending Medication.Journal of research in pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil and tadalafil) have been in widespread use for the safe and effective treatment of erectile dysfunction (ED) for nearly a decade. During that time, a relatively small number of patients have experienced adverse visual events, including nonarteritic anterior ischaemic optic neuropathy (NAION). In this article, post-marketing reports of adverse visual events along with other relevant literature on ocular safety related to PDE-5 inhibitor use are reviewed. Although a relatively small number of cases have been reported with a possible temporal association with PDE-5 inhibitor use, it has not been possible to conclude whether these events are coincidental or whether they are associated with effects of PDE-5 inhibitors on ocular circulation or on other structures of the eye. A careful review of pooled data from clinical trials for all three PDE-5 inhibitors, which contain well documented information about the dose and duration of exposure to the drug for a large number of patients, yields no evidence for an increased risk of NAION or other adverse ocular events associated with PDE-5 inhibitor use. However, the inherent limitations in interpreting results from clinical trials and potentially incomplete information from post-marketing surveillance preclude a definitive declaration that ocular safety will not be a concern for some patients with ED and co-morbid disease states. Despite the absence of a proven link between PDE-5 use and serious ocular disorders, physicians should continue to advise patients to stop use of a PDE-5 inhibitor and seek immediate medical attention in the event of a sudden loss of vision as a safety measure.
Indexed as
Identifiers
19132801What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.